About Spark Neuro
Spark Neuro is an applied neuroscience company. It collects and quantifies data to create machine-learning-based brain health biomarkers for clinical care and therapeutic discovery. It was founded in 2016 and is based in New York, New York.
Spark Neuro Patents
Spark Neuro has filed 1 patent.
Motor neurone disease, Rare diseases, Motor neuron diseases, Neurological disorders, Amyotrophic lateral sclerosis
Motor neurone disease, Rare diseases, Motor neuron diseases, Neurological disorders, Amyotrophic lateral sclerosis
Latest Spark Neuro News
Feb 2, 2023
nature reviews disease primers Abstract Medication overuse headache (MOH) is a secondary headache disorder attributed to overuse of acute headache medications by a person with an underlying headache disorder, usually migraine or tension-type headache. MOH is common among individuals with 15 or more headache days per month. Although MOH is associated with substantial disability and reductions in quality of life, this condition is often under-recognized. As MOH is both preventable and treatable, it warrants greater attention and awareness. The diagnosis of MOH is based on the history and an unremarkable neurological examination, and is made according to the diagnostic criteria of the International Classification of Headache Disorders third edition (ICHD-3). Pathophysiological mechanisms of MOH include altered descending pain modulation, central sensitization and biobehavioural factors. Treatment of MOH includes the use of headache preventive therapies, but essential to success is eliminating the cause, by reducing the frequency of use of acute headache medication, and perhaps withdrawing the overused medication altogether. Appropriate treatment is usually highly effective, leading to reduced headache burden and acute medication consumption. Access options $29.99 $79.00 VAT will be added later in the checkout. Tax calculation will be finalised during checkout. Buy article $32.00 Additional access options: Fig. 2: Putative cellular and molecular mechanisms of medication overuse headache. Fig. 3: Example of an electronic headache diary of a patient with chronic migraine and medication overuse headache. Fig. 4: Proposed prevention and treatment algorithm of medication overuse headache. References Peters, G. A. & Horton, B. T. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc. Staff. Meet. Mayo Clin. 26, 153–161 (1951). Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD). Institute for Health Metrics and Evaluation https://www.healthdata.org/gbd/2019 (2019). GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545–1602 (2016). Population Pyramid. Population pyramids of the World from 1950 to 2100. Population Pyramid https://www.populationpyramid.net (2019). Luvsannorov, O. et al. Primary headache disorders among the adult population of Mongolia: prevalences and associations from a population-based survey. J. Headache Pain 20, 114 (2019). World Health Organization. WHO methods and data sources for global burden of disease estimates 2000-2019. WHO https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/ghe2019_daly-methods.pdf (2020). Mathers, C. D., Vos, T., Lopez, A. D., Salomon, J. & Ezzatti, M. (ed.) National Burden of Disease Studies: A Practical Guide. Edition 2.0. Global Program on Evidence for Health Policy (World Health Organization, 2001). Grosse, S. D., Lollar, D. J., Campbell, V. A. & Chamie, M. Disability and disability-adjusted life years: not the same. Public Health Rep. 124, 197–202 (2009). Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743–800 (2015). World Health Organization. ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2nd ed. WHO https://apps.who.int/iris/handle/10665/42980 (2004). Steiner, T. J. et al. The Global Campaign turns 18: a brief review of its activities and achievements. J. Headache Pain 23, 49 (2022). Lau, C. I., Liu, M.-N., Chen, W.-H., Walsh, V. & Wang, S.-J. in Progress in Brain Research: Update on Emerging Treatments for Migraine Vol. 255 (eds Wang, S.-J. & Lau, C. I.) 371–402 (Elsevier, 2020). Haulică, I., Petrescu, G., Uluitu, M., Roşca, V. & Slătineanu, S. Influence of angiotensin II on dog pineal serotonin content. Neurosci. Lett. 18, 329–332 (1980). GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 5, 987–1012 (2018). Diener, H. C. & Dahlöf, C. in The Headaches (eds Olesen, J., Tfelt-Hansen, P. & Welch, K. M.) Ch. 115, 871–878 (Lippincott Williams & Wilkins, 2000). Oh, S. Y. et al. Clinical characteristics of medication-overuse headache according to the class of acute medication: a cross-sectional multicenter study. Headache 62, 890–902 (2022). FDA. Treating migraines: more ways to fight the pain. FDA https://www.fda.gov/consumers/consumer-updates/treating-migraines-more-ways-fight-pain (2017). Ashina, S., Lyngberg, A. & Jensen, R. Headache characteristics and chronification of migraine and tension-type headache: a population-based study. Cephalalgia 30, 943–952 (2010). Grazzi, L. et al. A preliminary analysis on the feasibility and short-term efficacy of a phase-III RCT on mindfulness added to treatment as usual for patients with chronic migraine and medication overuse headache. Int. J. Environ. Res. Public Health 19, 14116 (2022). Ljubisavljevic, M., Ignjatovic, A., Djordjevic, V., Pesic, M. H. & Ljubisavljevic, S. Depression, anxiety, stress, and health-related quality of life among patients with medication overuse headache in a tertiary headache center: a cross-sectional study. J. Neuropsychiatry Clin. Neurosci. 33, 132–143 (2021). Acknowledgements The authors thank T. P. Do for skilful assistance and for providing the initial sketches for Fig. 1. Author information Authors and Affiliations BIDMC Comprehensive Headache Center, Department of Neurology and Department of Anaesthesia, Critical Care and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA Sait Ashina Sait Ashina Gisela M. Terwindt Timothy J. Steiner Timothy J. Steiner Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Timothy J. Steiner & Rigmor H. Jensen Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea Mi Ji Lee Frank Porreca Cristina Tassorelli Cristina Tassorelli Todd J. Schwedt Hans-Christoph Diener Department of Neurology and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA Richard B. Lipton Richard B. Lipton Gisela M. Terwindt Timothy J. Steiner Mi Ji Lee Frank Porreca Cristina Tassorelli Todd J. Schwedt Rigmor H. Jensen Hans-Christoph Diener Richard B. Lipton Contributions Introduction (S.A., R.B.L. and T. J. Steiner); Epidemiology (S.A., T. J. Steiner and R.B.L. ); Mechanisms/pathophysiology (S.A., G.M.T., F.P. and C.T. ); Diagnosis, screening and prevention (S.A., G.M.T., T. J. Schwedt and R.H.J. ); Management (S.A., M.J.L., R.H.J. and H.-C.D. ); Quality of life (S.A., T. J. Steiner, T. J. Schwedt and R.B.L. ); Outlook (S.A., F.P., R.H.J., H.-C.D. and R.B.L. ); Overview of Primer (S.A.). Corresponding author Competing interests S.A. received honoraria for consulting from Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel NeuroPharma, Linpharma, Lundbeck, Novartis, Satsuma, Supernus, Teva, Theranica, Percept. S.A. is an associate editor for Neurology Reviews, Frontiers in Neurology and BMC Neurology, serves on the advisory board for the Journal of Headache and Pain, and is a member of the Education Committee of the International Headache Society. G.M.T. reports consultancy support from Novartis, Allergan, Lilly, Teva, Lundbeck, and independent support from the Dutch Organization for Scientific Research, the Dutch Heart and Brain Foundations, IRRF and Dioraphte. M.J.L. received honoraria as a consultant and/or speaker for Eli Lilly, Teva, Sanofi-Aventis, SK Pharma and YuYu Pharma; has been the principal investigator or co-investigator in trials sponsored by Eli Lilly, Novartis, Teva (Otsuka), Allergan, Biohaven, Yuhan Company, Samjin Pharm, and DongA ST; received research support from National Research Foundation of Korea. M.J.L. is an associate editor of Cephalalgia. F.P. has served as a consultant or received research funding from Amgen, Acadia, Teva, Eli Lilly, Lundbeck, Allergan, AbbVie, AstraZeneca, Ipsen and PeptideLogic and is a founder of Catalina Pharma and Axon Therapeutics. C.T. has received personal fees from AbbVie, Allergan, Biohaven, Eli Lilly, Lundbeck, Novartis and Teva. C.T. has received research funding from the European Commission, the Italian Ministry of Health and Migraine Research Foundation. T. J. Schwedt has received personal income from AbbVie, Allergan, Biohaven, Click Therapeutics, Eli Lilly, Equinox, Lundbeck, Novartis, Tonix and Weber & Weber. T. J. Schwedt holds stock options in Aural Analytics and Nocira and has received royalties from UpToDate. T. J. Schwedt has received research funding from the American Migraine Foundation, Amgen, Henry Jackson Foundation, NIH, Patient Centered Outcomes Research Institute, SPARK Neuro and the US Department of Defense. R.H.J. has received honoraria for lectures and/or patient leaflets from MSD, Berlin-Chemie Menarini, ATI, Novartis, Teva, Allergan, Lundbeck and Pfizer, and has been principal investigator in studies sponsored by Eli Lilly, Lundbeck and ATI. H.-C.D. received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Ipsen, Lilly, Novartis, Pfizer and Teva. The German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union support his headache research. H.-C.D. serves on the editorial boards of Cephalalgia and Lancet Neurology. H.-C.D. is member of the Clinical Trials Committee of the IHS. R.B.L. is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH and FDA. R.B.L. also receives support from the National Headache Foundation and the Marx Foundation. R.B.L. serves on the editorial board of Neurology, is senior adviser to Headache, and associate editor to Cephalalgia and has reviewed for the NIA and NINDS, holds stock options in Biohaven Holdings, Manistee and CntrlM; serves as consultant, advisory board member, or has received honoraria or conducted research funded by Allergan/AbbVie, American Academy of Neurology, American Headache Society, Amgen, Biohaven, Dr Reddy’s (Promius), Electrocore, Eli Lilly, GlaxoSmithKline, Grifols, Lundbeck, Pernix, Pfizer, Teva, Trigemina, Vector, Vedanta. R.B.L. receives royalties from Wolff’s Headache 7th and 8th Edition, Oxford University Press, 2009, Wiley and Informa. T. J. Steiner declares no competing interests. Peer review Peer reviewer information Nature Reviews Disease Primers thanks S. Cevoli, L. Grazzi, P. Martelletti and L. Stovner for their contribution to the peer review of this work Additional information Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Related links Rights and permissions Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Spark Neuro Frequently Asked Questions (FAQ)
When was Spark Neuro founded?
Spark Neuro was founded in 2016.
Where is Spark Neuro's headquarters?
Spark Neuro's headquarters is located at 80 8th Avenue, New York.
What is Spark Neuro's latest funding round?
Spark Neuro's latest funding round is Loan.
How much did Spark Neuro raise?
Spark Neuro raised a total of $14.18M.
Who are the investors of Spark Neuro?
Investors of Spark Neuro include Paycheck Protection Program, Plug and Play Japan, Tornante Company, Thiel Capital, Fort Ross Ventures and 3 more.